Suparna Wedam
5PUBLICATIONS
21CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (5)
Sort by Publication Date:
|Aug 22, 2025
US Food and Drug Administration Approval Summary: Inavolisib With Palbociclib and Fulvestrant for Endocrine-Resistant, PIK3CA-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, Locally Advanced or Metastatic Breast Cancer.Suparna Wedam, Preeti Narayan, Haley Gittleman
|Oct 29, 2021
U.S. FDA Drug Approvals for Breast Cancer: A Decade in Review.Shaily Arora, Preeti Narayan, Christy L Osgood
|Oct 29, 2021
U.S. FDA Drug Approvals for Gynecological Malignancies: A Decade in Review.Shaily Arora, Preeti Narayan, Gwynn Ison
|Feb 10, 2021
Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Prior Therapies Work Group.Raymond U Osarogiagbon, Diana Merino Vega, Lola Fashoyin-Aje
|Oct 15, 2020
FDA Approval Summary: Tucatinib for the Treatment of Patients with Advanced or Metastatic HER2-positive Breast Cancer.Mirat Shah, Suparna Wedam, Joyce Cheng
Pageof 1
Frequent Collaborators
2 joint publications
Xiao Hong Chen
2 joint publications
Amna Ibrahim
2 joint publications
Melanie Royce
2 joint publications
Tatiana M Prowell
2 joint publications
Jennifer J Gao
1 joint publications
Kirsten B Goldberg
1 joint publications
Diana Merino Vega
1 joint publications
Lola Fashoyin-Aje
1 joint publications
Sol Atienza
1 joint publications
Tithi Biswas
